April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Evaluation of Viral and Human Retinal Promoters in AAV8 Vectors
Author Affiliations & Notes
  • Kayleigh Kaneshiro
    Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, Bethesda, Maryland
  • Zhijian Wu
    Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, Bethesda, Maryland
  • Tiansen Li
    Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, Bethesda, Maryland
  • Paul Sieving
    Section for Translational Research in Retinal and Macular Degeneration, National Institute on Deafness and Other Communication Disorders and National Eye Institute, Bethesda, Maryland
  • Peter Colosi
    Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  Kayleigh Kaneshiro, None; Zhijian Wu, None; Tiansen Li, None; Paul Sieving, None; Peter Colosi, None
  • Footnotes
    Support  NEI Intramural Program
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 491. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kayleigh Kaneshiro, Zhijian Wu, Tiansen Li, Paul Sieving, Peter Colosi; Evaluation of Viral and Human Retinal Promoters in AAV8 Vectors. Invest. Ophthalmol. Vis. Sci. 2011;52(14):491.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Only a small number of retinal promoters have been extensively characterized in the context of gene therapy vectors. Promoters with retinal-specific, pan-neuronal expression patterns would be desirable for certain therapeutic applications, but none have been well characterized in gene transfer vectors. The retinoschisin gene, which encodes a protein that maintains retinal structure, shows such an expression pattern. In this study, we characterized a promoter composed of the human retinoschisin proximal promoter and the human interphotoreceptor retinoid-binding protein enhancer (RS/IRBP). This promoter was evaluated for strength and tropism when used to drive EGFP expression in the context of a subretinally-administered, adeno-associated virus type 8 (AAV8) vector. Identical vectors using the well characterized cytomegalovirus immediate early (CMV) and human rhodopsin kinase (RK) promoters were evaluated for comparison.

Methods: : AAV8 EGFP vectors employing the RS/IRBP (promoter -745 to +42, enhancer -1635 to -1375), RK (-112 to +183), or CMV (-582 to +183) promoters were administered to adult, wild type C57BL/6 mice at a dose of 3e8 vector genomes / eye by subretinal injection. The expression cassettes featured a CMV/human beta-globin chimeric intron positioned 5’ of the EGFP cDNA and the human beta-globin 3’ UTR and polyadenylation site. The mice were sacrificed 3 weeks after injection, and the retinas were evaluated histologically and for EGFP fluorescence. Photographs of representative sections were taken.

Results: : The CMV promoter produced the strongest EGFP expression which was located in the photoreceptor layer and retinal pigment epithelium (RPE). The RK promoter produced photoreceptor-specific fluorescence which was approximately 4-fold weaker than the CMV promoter. The RS/IRBP promoter was approximately 2-fold weaker than the RK promoter, and fluorescence was located in the photoreceptor layer. Weak fluorescence was sporadically detected in some RPE cells.

Conclusions: : The RS/IRBP promoter is a relatively strong promoter in photoreceptors. It may be useful in the construction of AAV vectors designed to treat X-linked retinoschisis.

Keywords: gene transfer/gene therapy • gene/expression • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×